EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lipid‐Based Nanotherapeutics for Inflammatory Disorders: Current Progress and Future Perspectives

Yumna Zaheer iD, Syeda Zunaira Bukhari iD, Unqa Mustafa iD, Muhammad Usman Munir iD, Azka Naveed iD, Haji Muhammad Shoaib Khan iD, Sadia Zafar Bajwa iD, Mingwu Shen iD, Ayesha Ihsan iD

WIREs Nanomedicine and Nanobiotechnology · 2026

DOI: 10.1002/wnan.70081 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, 2026. Verfasst von Yumna Zaheer und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C, PIEAS), Faisal…. Hauptthemen laut MEDLINE: Lipids, Inflammation, Nanoparticles, Nanomedicine. Die Arbeit nennt 148 Literaturangaben. Gefördert von: Higher Education Commission, Pakistan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant inflammatory responses are crucial indicators of the onset and progression of diverse pathologies, including metabolic syndromes, autoimmune disorders, and neuroinflammation. The intrinsic intricacy and heterogeneity of these signaling pathways require innovative therapeutic approaches that allow precise immunomodulation while alleviating systemic toxicity. Lipid‐based nanocarriers (LBNCs), including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, have emerged as transformative platforms to deliver a variety of therapeutic agents. The clinical maturity of these systems, catalyzed by the global success of lipid‐based RNA vaccines, has established an initial safety and scalability of this framework, which is now being transitioned toward chronic inflammatory management. This review critically evaluates the structure–function relationships of LBNCs, examining how specific physicochemical attributes dictate their interaction with inflamed tissues. We analyze the molecular mechanisms by which LBNCs' architecture modulates key inflammatory regulators, such as cytokine networks and oxidative pathways, to achieve superior therapeutic control. Furthermore, we scrutinize the strategic selection of delivery routes and their direct impact on site‐specific biodistribution and patient compliance. By addressing current bottlenecks in long‐term immunocompatibility and regulatory characterization, this review provides a roadmap for engineering the next generation of bio‐responsive anti‐inflammatory nanomedicines. Collectively, these insights position LBNCs as a transformative paradigm for refining the precision and efficacy of modern anti‐inflammatory therapy. This article is categorized under: Biology‐Inspired Nanomaterials > Lipid‐Based Structures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidsInflammationNanoparticlesNanomedicineHumansAnimalsDrug Delivery Systems

Stichwörter der Autor:innen

anti‐inflammatory agentsdrug deliveryinflammatory conditionsinflammatory microenvironmentlipid‐based nanosystemsnanothera peutics

Substanzen

Lipids

Autor:innen und Institutionen

  • National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C, PIEAS), Faisalabad, Pakistan.
  • Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
  • College of Pharmacy, University of Health Sciences Lahore, Lahore, Pakistan.
  • College of Chemistry, Chemical Engineering, and Biotechnology, Donghua University, Shanghai, China.

ORCID-Profile: Yumna Zaheer, Syeda Zunaira Bukhari, Unqa Mustafa, Muhammad Usman Munir, Azka Naveed, Haji Muhammad Shoaib Khan, Sadia Zafar Bajwa, Mingwu Shen, Ayesha Ihsan

Förderung

  • Higher Education Commission, Pakistan

Zitieren

APA

Zaheer, Y., Bukhari, S. Z., Mustafa, U., Munir, M. U., Naveed, A., Khan, H. M. S., Bajwa, S. Z., Shen, M., & Ihsan, A. (2026). Lipid‐Based Nanotherapeutics for Inflammatory Disorders: Current Progress and Future Perspectives. WIREs Nanomedicine and Nanobiotechnology. https://doi.org/10.1002/wnan.70081

Vancouver

Zaheer Y, Bukhari SZ, Mustafa U, Munir MU, Naveed A, Khan HMS, et al. Lipid‐Based Nanotherapeutics for Inflammatory Disorders: Current Progress and Future Perspectives. WIREs Nanomedicine and Nanobiotechnology. 2026. doi:10.1002/wnan.70081

BibTeX
@article{Zaheer2026,
  author = {Zaheer, Yumna and Bukhari, Syeda Zunaira and Mustafa, Unqa and Munir, Muhammad Usman and Naveed, Azka and Khan, Haji Muhammad Shoaib and Bajwa, Sadia Zafar and Shen, Mingwu and Ihsan, Ayesha},
  title = {Lipid‐Based Nanotherapeutics for Inflammatory Disorders: Current Progress and Future Perspectives},
  journal = {WIREs Nanomedicine and Nanobiotechnology},
  year = {2026},
  doi = {10.1002/wnan.70081}
}
Kostenlos starten →